Olanzapine is a second generation atypical antipsychotic, with affinity to multiple receptor systems including serotonin, dopamine, muscarinic, adrenergic and histamine H1. 1 However, emerging reports indicate that olanzapine's antipsychotic, antidepressant and antimanic effects may be due to its modulation of numerous brain genes/proteins. 2 By the same token, some of its side effects such as increased propensity for weight gain may be due to its effects on multiple metabolic genes resident in brain, muscle or liver. 2 Recently, Engl et al. 3 provided evidence for olanzapine's action on glycogen synthesis and insulin signaling in L6 skeletal muscle cells. These authors showed that acute administration of olanzapine to cultures of L6 rat skeletal muscle cells caused reductions in glycogen content in a dose and time dependent manner. Olanzapine inhibited insulin stimulated IRS-1 tyrosine phosphorylation and IRS-1 associated PI3K activity. 3 Additionally, olanzapine diminished phosphorylation of AKT and GSK-3 and increased phosphorylation of glycogen synthase, thereby inhibiting glycogen synthesis. 3 These authors concluded that olanzapine inhibits the classical insulin-signalling cascade and that this inhibition may lead to induction of insulin resistance in olanzapine-treated patients. 3 Recently, we provided evidence that chronic administration of olanzapine to rats for 21 days caused significant upregulation of 38 genes and downregulation of 31 genes in frontal cortex. 2 Multiple genes involving energy production were modulated significantly by olanzapine. Some of the upregulated genes included insulin 2, pyruvate kinase, CART, muscle glycogen phosphorylase and calpain 8. In contrast, several metabolic genes were downregulated such as sucrase-isomaltase, UDP glycosyltransferase 2 family and carbohydrate sulfotransferase 3. The overall picture emerging from this study was that chronic administration of olanzapine in rats increased energy production in brain by greater provision of glucose for local use (Figure 1) . 2, 3 For example, olanzapine upregulated pyruvate kinase, an enzyme that catalyzes the formation of pyruvate and ATP from phosphoenolpyruvate and ADP. Interestingly, pyruvate kinase polymorphisms have been associated with both type 2 diabetes and schizophrenia. 4, 5 Olanzapine also upregulated glycogen phosphorylase, an important enzyme involved in glycogen degradation which provides additional glucose for local brain energy expenditure.
2 By the same token, olanzapine stimulated synthesis of insulin 2 (the rat equivalent of human insulin), either in response to increases in glucose or due to other unknown metabolic factors. 2 Olanzapine reduced the level of sucrase-isomaltase to help conserve glucose in disaccharide form. 2 Finally, olanzapine upregulated CART which increases feeding behavior and leads to more glucose production. 2 Review of data published by Engl et al. 3 and those by our laboratory, 2 suggests that olanzapine increases glucogenesis in brain and muscle by upregulating glycogen phosphorylase and phosphorylating (inactivating) glycogen synthase in the respective target tissues. The net product of both pathways is increased glucose production, which by necessity leads to increased insulin production and could lead to endorgan insulin resistance. We propose that olanzapine's propensity towards increased glucose production may be of therapeutic relevance, since it provides more energy for local expenditure in brain to improve synaptic transmission in disorders like schizophrenia, depression and manic-depressive illness. Clearly, glucogenesis in brain is, one of several biochemical pathways, used by olanzapine to help in improving synaptic neurotransmission in the diseased brain. Some of the alternative pathways involved in olanzapine's action in brain include upregulation of Reelin mRNA and protein 6 and decreases in NMDA3B and RGS2 mRNA and proteins, all leading to improving glutamatergic neurotransmission. Indeed, as shown recently by Lieberman et al., 7 olanzapine and not haloperidol, was capable of diminishing brain gray Figure 1 Alternative biochemical pathways involved in glucogenesis and energy production in rat brain and muscle following administration of olanzapine. matter loss in subjects with schizophrenia after a 3 month treatment protocol supporting its beneficial effects in ameliorating cognitive deficits in several psychiatric disorders.
A possible impact of the neuroD2 transcription factor on the development of drug abusing behavior A recent study by Lin et al.
1 has shown that the transcription factor neuroD2 regulates amygdala development and emotional learning in mice. In neuroD2-null mice, the lateral and basolateral amygdala was undeveloped and neuroD2 heterozygous mice had fewer neurons in this region. Moreover, neuroD2 heterozygous mice revealed a profound deficit in emotional learning when compared to wildtype controls in terms of decreased anxiety behaviors in unconditioned fear tests. The present results of a post-mortem mRNA expression study of the neuroD2 gene in human brain suggest that the neuroD2 gene might be one of the crucial factors in the development of drug abusing behavior in humans.
NeuroD2 is a basic helix-loop-helix transcription factor with important functions during development of the nervous system. 2 In adult central nervous system (CNS), sustained neuroD2 mRNA expression is detected in specific brain regions, including the hippocampus, cortex and cerebellum. 3 Lin et al. could demonstrate that neuroD2 is necessary not only for the amygdala development in mice but also that the dose of the neuroD2 gene is critical for the regulation of molecules that underlie emotional learning, as the AMPA receptor, the gamma aminobutyric acid (GABA)-A receptor and Ulip, a protein that is involved in neuronal plasticity. 1 Furthermore, neuroD2 heterozygous mice showed a decreased response to fear conditioning and unconditioned fear analysis. 1 There is increasing evidence that addiction not only emerges from neuronal mechanisms of learning and memory, with involvement of the GABAergic and glutamatergic systems, but also represents a risktaking behavior itself. [4] [5] [6] Additionally, suicidal behavior has a high comorbidity with risk-related personality traits, with the highest risk-taking behavior in completed suicide by violent means. 7 These results suggest that the neuroD2 gene might also control risktaking behaviors in humans. Therefore, we performed a post-mortem mRNA expression study of the neuroD2 gene in the human brain tissue cortex, hippocampus, amygdala and hypothalamus of drug abusers, suicide victims and controls.
Brain specimens were obtained during routine autopsy at the Institute for Legal Medicine of the Ludwig-Maximilians-University Munich and derived from 11 individuals who died as a consequence of an opiate dependence (nine men, two women, mean age 31.277.6 years; post-mortem interval (PMI): 16.475.2 h) and from nine suicide victims (six men three women, mean age 44.5715.0 years; PMI: 20.178.4 h). Six of them have committed violent suicides, for example, hanging (n = 2), penetrating lesions (n = 3) and jumping from height (n = 1), and three were employing so-called soft suicide methods, such as intoxication with drugs or other substances. The control tissues were obtained from 16 persons who died suddenly from diseases not directly involving the CNS. The causes of the deaths were the following: acute cardiac failure (n = 7), accident (n = 3) and homicide (n = 6). The clinical, respective, medical data sheets of the control individuals were available to the Institute for Legal Medicine of the Ludwig-Maximilians-University Munich, and did not give any hint on lifetime psychiatric or neurological disorders. According to the medical records, there was no history of psychopharmacological medication, alcohol or drug abuse. Additionally a toxicological report for all individuals was provided, whereas informations on pre-existing psychiatric disturbances were missing for the suicide victims. All individuals were Caucasians from the same geographical region in southern Germany.
Sections were taken from the orbitofrontal cerebral cortex, the posterior hippocampus at the coronal level of the lateral geniculate nucleus, the amygdala and
